Quest Diagnostics Inc vs RadNet, Inc., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where DGX and RDNT diverge most: on net margin, DGX reads 9.2% and RDNT reads -0.9%; on return on equity, DGX reads 13.6% and RDNT reads -1.5%. The rest of the comparable metrics sit closer together. What DGX's price implies is a bet that sits within the historical range (whole-company basis). What RDNT's price implies is a somewhat stretched bet versus history (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | DGX | RDNT |
|---|---|---|
| Price | $234.94 | $75.49 |
| Market cap | $26.3B | $5.9B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Mature | Growth |
| Implied growth (priced in) | -0.7% | — |
| P/E | 24.9 | — |
| P/B | 3.37 | 4.26 |
| P/S | 2.28 | 2.62 |
| EV/EBITDA | 14.2 | 27.2 |
| Revenue growth | +9.9% | +18.8% |
| Operating margin | 15.1% | 6.3% |
| Net margin | 9.2% | -0.9% |
| Return on equity | 13.6% | -1.5% |
| Return on assets | 6.3% | -0.5% |
| Return on invested capital | 9.6% | 1.9% |
| FCF yield | 5.1% | 5.2% |
| Dividend yield | 0.8% | — |
| Debt / equity | 0.72 | 0.98 |
| Current ratio | 1.59 | 1.48 |
| Altman Z (solvency) | 7.70 | 1.88 |
| Piotroski F (quality) | 7 / 9 | 5 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.